Agreements reached under this partnership
Business alliance- 1
An exclusive global license agreement covering the technology to develop brincidofovir (BCV) as a treatment and preventive drug for multiple sclerosis (MS)
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
This matter will have no impact on the consolidated earnings outlook for the fiscal year ending December 2026.
| Item | Details |
|---|---|
| Name of alliance partner | U.S. Department of Health and Human Services (HHS) |
| Alliance partner's business activities | Research and development through the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH) |
| Alliance partner's location | United States |
| Type of alliance | Business alliance |
| Details of the alliance | An exclusive global license agreement covering the technology to develop brincidofovir (BCV) as a treatment and preventive drug for multiple sclerosis (MS) |
| Impact on Business Performance | This matter will have no impact on the consolidated earnings outlook for the fiscal year ending December 2026. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To develop a new treatment for multiple sclerosis targeting the Epstein-Barr virus, leveraging BCV's ability to selectively inhibit Epstein-Barr virus-positive cells and its high antiviral activity.